This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
3/10/2022
Good morning and welcome to the Genosha fourth quarter 2021 conference call. At this time, all participants are on a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to Daniel Ferry of LifeSci Advisors. Please proceed.
Thank you, Operator, and good morning, everyone. Earlier today, we issued a press release that outlines the topics we plan to discuss today. This release is available at Genosha.com under the Investors tab. During the call today, Chip Clark, President and CEO, will provide a brief corporate update, and the company's Chief Financial Officer, Diantha Duvall, will review the financial results. After the prepared remarks, we will open up the call for Q&A. And Chip, Diantha, Tom Davis, Genosha's Chief Medical Officer, Jessica Fleckner, Genosha's Chief Scientific Officer, And Ray Stapleton, Chief Technology Officer, will then be available to answer your questions. Before we begin, this presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995, including statements related to Gen 11 and the anticipated timing of top-line results from its Phase I to A clinical trial, the planet manufacturing process, and research efforts, including with regard to ATLAS and inhibogens. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Each forward-looking statement is subject to risks and uncertainties, and actual outcomes and results could differ materially from those projected in such statements. The forward-looking statements in this presentation speak only as of the original date of this presentation. Genosha expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in Genosha's 2020 Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission and available on Genosha's website. It is now my pleasure to pass the call over to Chip.
Thanks, Dan, and thank you all for joining us today. I'm pleased to share Genosha's progress with you. Most notably, we recently revealed that we'll soon share initial results from our Titan clinical trial for GEN11, which is our neoantigen-targeted peripheral T-cell therapy product candidate. Let me remind the audience that GEN11 is comprised of neoantigen-specific, peripherally-derived T-cells, or NPTs, that we screen for patient-specific neoantigens with our ATLAS platform. The platform identifies through a bioassay each patient's anti-tumor neoantigens and pro-tumor inhibigens. Our PLANET process selectively expands T-cells specific to the ATLAS-identified anti-tumor neoantigens. As of March 3rd, we had completed screening 23 patient samples with ATLAS. On average across these samples, ATLAS has prioritized 12 neoantigens with an average, a range rather, of 0 to 43, and identified 16 inhibigens with a range of 1 to 82 across the patients. From there, 17 patient samples have entered the PLANET process. 100% have either successfully yielded a released drug product, 14, or continue in process, 3. Of the 14 manufactured Gen 11 drug products, six have been administered to patients across both the multi-dose and single-dose cohorts, with the remaining eight available for dosing upon patient need. We expect to share initial data principally from the first five patients in the poster presentation at AACR. We will also present two other posters at AACR. One will provide additional color on the Gen 11 planet manufacturing process and drug product characteristics. The other will showcase the continued evolution of the inhibigent story made possible by the neoantigen selection capabilities of ATLAS. Finally, we are planning to host an investor call during AACR covering all three presentations. We will announce the exact timing shortly. I'm also pleased to welcome John Lunger, Chief Patient Supply Officer at Adaptimmune, to our Board of Directors. As the adage goes, process is product. So with successful scale-up and delivery of our drug product candidates a critical driver of long-term success, I am confident John's experiences and expertise will prove invaluable to us and our board. I also would like to remind you that in January, we entered into an R&D collaboration and option agreement with Janssen Biotech Incorporated, one of the Janssen pharmaceutical companies of Johnson & Johnson, to explore the immunogenicity of neoantigens and the impact of inhibogens in the context of vaccine therapies for cancer. So as you can see, we continue to make progress on multiple fronts. I am grateful to the Genosha team for many things, including their heart, tenacity, and agility. I'm now going to pass the call over to Diantha to summarize our financials from this quarter before opening the call up to questions. Diantha?
You're reading a preview of the GNCA Q4 2021 earnings call.
Free account.
